Edgewise Therapeutics Soars 50%: Key Reasons Behind the Surge
Edgewise Therapeutics NASDAQ: EWTX is up 50% in a single session and 450% from recent lows for a reason. Its novel, oral, selective treatment for obstructive hypertrophic cardiomyopathy did remarkably well in early trials. The news is important because hypertrophic cardiomyopathy or HCM for short, is the leading cause of sudden cardiac-related death in people…